Interesting observation, Dan… the control group, upon eventing, likely exhibited a more mesenchymal signature on their returning tumors, which has been proven to often be the case. This could, in part at least, account for why the rGBM control arm that crossed over to DCVax-L treatment did so well. Mesenchymal usually marks the worst and most aggressive tumor (likely because it is chock full of antigens) except for when DCVax-L is used, as having all those antigens makes it easier for DCVax-L to mobilize the Tcells to find and target it.
News 
Market Data 
Discover 
